Minimising the dosage-limiting toxicities of foscarnet induction therapy

Drug Safety

Volumn 16, Issue 4, 1997, Pages 258-266

  Jayaweera, Dushyantha T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CALCIUM; ELECTROLYTE; FOSCARNET; GANCICLOVIR;

ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DOSE CALCULATION; DRUG INFUSION; DRUG USE; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE DISTURBANCE; FATIGUE; GENITAL ULCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPHOSPHATEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUBULE; NAUSEA; NEPHROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PARESTHESIA; PATIENT MONITORING; PERSONAL HYGIENE; PRIORITY JOURNAL; SEIZURE; SKIN TINGLING; SYMPTOM;

EID: 0030902148     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199716040-00003     Document Type: Article

References (40)

1. Jabs DA, Enger C, Bartlet JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989; 107: 75-80
2. Crumpacker CS, Heath-Chiozi M. Overview of cytomegalovirus infections in HIV-infected patients: current therapies and future strategies. J Acquir Immune Defic Syndr 1991; 4 Suppl. 1: S1-S5
3. Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988; 158: 449-56
4. Jacobson MA, Mills J. Serious Cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis and treatment. Ann Intern Med 1988; 108: 585-94
5. Martin DF, Parks DJ, Mellow S, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994; 112: 1531-9
6. Hitchcock MJM, Jaffe HS, Martin JC, et al. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem Chemother 1996; 7: 115-27
7. SOCA and ACTG. Mortality and toxic effects associated with ganciclovir and foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995; 115: 65-73
8. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy with monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996; 114: 23-33
9. Palestine AG, Polis MA, De Smet MD, et al. A randomized, control clinical trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115: 665-73
10. Polis MA, De Smet MD, Baird BF, et al. Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonate (foscarnet). Am J Med 1993; 94: 175-80
11. Katalama C, Dohlin E, Caumes E, et al. Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. J Acquir Immune Defic Syndr 1992; 5 Suppl. 1: S18-24
12. Jacobson M, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients treated with acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989; 33: 736-41
13. Benson P, Nahass R, Deresinki S, et al. Safety of oral therapy vs intravenous hydration during induction therapy with intravenous foscavir [abstract no. 299]. Conference on Retroviruses and Opportunistic Infections: 1997 Jan 22-26; Washington
14. Deray G, Cacoub P, Le Hoang P, et al. Foscarnet-induced acute renal failure and effectiveness of hemodialysis [letter]. Lancet 1987; II: 216
15. Deray G, Martinez F, Katalama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989; 9: 316-21
16. Cacoub P, Deray G, Baumelou A, et al. Acute renal failure induced by foscarnet: 4 cases. Clin Nephrol 1988; 29: 315-8
17. Navarro JF, Querreda C, Moreno A, et al. Renal tubular acidosis following treatment with foscarnet [letter]. AIDS 1995; 9: 1389-90
18. Trolliet P, Dijoud F, Cotte L, et al. Crescentic glomerulonephritis and crystals within glomerular capillaries in an AIDS patient treated with foscarnet. Am J Nephrol 1995; 15: 256-9
19. Farese RV, Schambelan M, Hollander H, et al. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis. Ann Intern Med 1990; 112: 955-6
20. Nyberg G, Svalander C, Blohme I, et al. Tubularinterstitial nephritis caused by the antiviral agent foscarnet. Transplant Int 1989; 2: 223-7
21. Beaufils H, Deray G, Katalama C, et al. Foscarnet and crystals in glomerular capillary lumens [letter]. Lancet 1988; I: 755
22. Jayaweera DT, White G, Moreno J. Pre-treatment with hydration and electrolytes may prevent dose limiting toxicities during foscarnet induction therapy. Gentourin Med 1995; 71: 414-5
23. Astra. Foscavir® (foscarnet) package insert
24. Morales JM, Munoz MA, Zatariain GF, et al. Reversible acute renal failure caused by the combined use of foscarnet and cyclosporin in organ transplanted patients [letter]. Nephrol Dial Transplant 1995; 10: 882-3
25. Noormohamed FH, Youle MS, Tang B, et al. Foscarnet-induced changes in plasma calcium and magnesium in HIV seropositive patients. Antiviral Ther 1996; 1 (3): 172-9
26. Jacobson MA, Gambertoglio JG, Aweeka FT, et al. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 1942; 72: 1130-5
27. Youle MS, Clabour J, Gazzard B, et al. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine [letter]. Lancet 1988; I: 1455-6
28. Gearhart MO, Sorg TB. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders. Ann Pharmacother 1943; 27: 285-9
29. Van Scoy M, Loghman-Adham M, Onsgard M, et al. Mechanism of phosphaturia elicited by administration of phosphonoformate in vivo. Am J Physiol 1988; 255: F984-F994
30. +-phosphate cotransport in opossum kidney cells. Am J Physiol 1992; 263: 301-10
31. Lor E, Liu YQ. Neurological sequelae associated with foscarnet therapy. Ann Pharmacother 1994; 28: 1035-7
32. Fitzgerald E, Goldman HM, Miller WG, et al. A penile ulceration in a patient with the acquired immunodeficiency syndrome. Arch Dermatol 1995; 11: 1447-52
33. Moyle G, Barton S, Gazzard BG. Penile ulcerations with foscarnet therapy. AIDS 1993; 7: 140-1
34. Caumes E, Gatineau M, Bricaire F, et al. Foscarnet-induced vulval erosion [letter]. Am Acad Dermatol 1995; 28: 799
35. Van Der Pijl JW, Frissen PHJ, Reiss P, et al. Foscarnet and penile ulceration [letter]. Lancet 1990; 335: 286
36. Dusserre N, Lessard C, Paquett N, et al. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS 1995; 9: 833-41
37. Bakker-Woudenberg L, Lokerse AJMAF, Kate TM. Increased efficacy of ganciclovir and foscarnet inhibition of cytomegalovirus replication in vitro by encapsulation in liposomes. Scan J Infect Dis 1991; 74: 54-7
38. Omar RF, Dusserre N, Desormeaux A, et al. Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet. Antimicrob Agents Chemother 1995; 39: 1973-8
39. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213-20
40. Sandsstrom EG, Kaplan JC, Byington RE, et al. Inhibition of human T cell lymphotropic virus type III in vitro by phosphonoformate [letter]. Lancet 1985; I: 1480